Search results for "Therapies"

showing 10 items of 124 documents

Efficiency of Hospital Expenses Projects Funded Through Partnership with an NGO Case Study

2017

In the context of limited resources of a public hospital, constrained by rigid regulations and lowcapacity to invest in the purpose of satisfying the raising needs of the patients, the health facilityembraced the solutions to partner with an NGO. In partnership with Association of Psychiatric Hospital Dr. Gheorghe Preda Sibiu (ASPPS) alarge number of projects have been developed. The projects aimed to create new means andmethods for complementary and ocupational therapy and to ensure a friendly and suportiveenvironement for the patients. With rather modest financial resources but maximum eficiency and voluntary work, manymodern facilities were created, some even in premiere.

complementary therapiespartnership with NGOefficiencylcsh:HB71-74lcsh:Economics as a sciencelcsh:Businesslcsh:HF5001-6182Ovidius University Annals: Economic Sciences Series
researchProduct

Alternative psychotherapies: Conceptual elucidation and epidemiological framework

2020

This article elucidates and defines alternative psychotherapies, as well as describes the variables that explain why some professional psychologists are prone to endorse these practices. First, the novel concept of “complementary and alternative psychotherapies” (CAP) is defined within the framework of the established hierarchy of clinical evidence. Second, we report a literature review to aid understanding of the main variables explaining why some clinicians prefer CAP. We review rejection of scientific reasoning, misconceptions about human nature, and pragmatic limitations of evidence-based practice.

evidence-based psychologymedicine.medical_specialtyEvidence-based practicePsychotherapistalternative psychotherapiesalternative medicineEpidemiologypseudoscienceAlternative medicinemedicinePsychologyCAPGeneral Psychology
researchProduct

Nueva era en el combate contra el cáncer: Evolución y cáncer: progreso y tratamiento de tumores

2013

L’oncohematologia ha assistit en les últimes dècades a importants avenços en el tractament i supervivència. La toxicitat derivada de la quimioteràpia clàssica i la necessitat de millorar l’eficàcia i tolerància als tractaments han fet que es desencadene un allau d’activitat investigadora que constantment proporciona fruits. Gran part d’aquest esforç s’ha enfocat al desenvolupament de «teràpies diana» dirigides contra determinades alteracions funcionals, clau per a la supervivència de la cèl·lula tumoral. Així es pretén aconseguir major eficàcia en el tractament i que el pacient pague un menor cost en toxicitat. Avenços en altres disciplines de l’oncologia com l’epidemiologia, la cirurgia i …

evolucióncribado poblacionalmecanismes de resistènciafàrmacs antidianaresistance mechanismsbiologia; evolució; genèticaterapias dirigidas; fármacos anti diana; inhibidores tirosin kinasa; mecanismos de resistencia; cribado poblacionalevolutiontyrosine kinase inhibitorsteràpies dirigides; fàrmacs antidiana; inhibidors tirosina-cinasa; mecanismes de resistència; cribatge poblacionalinhibidores tirosin kinasageneticsteràpies dirigidesanti-target drugsbiologygenèticascreeningtargeted therapies; anti-target drugs; tyrosine kinase inhibitors; resistance mechanisms; screeningcribatge poblacionalmecanismos de resistenciatargeted therapiesevolución; biología; medicinaterapias dirigidasevoluciófármacos anti dianabiologíabiology; evolution; geneticsmedicinabiologiainhibidors tirosina-cinasa
researchProduct

Classification of current anticancer immunotherapies.

2014

© 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

immunostimulatory cytokinesmedicine.medical_treatmentReviewBioinformaticsDNA-based vaccinesEfficacy0302 clinical medicineCancer immunotherapyNeoplasmspeptide-based vaccines0303 health sciencesPatología//purl.org/becyt/ford/3.1 [https]CANCER3. Good healthMedicina BásicaOncologycheckpoint blockers030220 oncology & carcinogenesisQR180//purl.org/becyt/ford/3 [https]ImmunotherapyCIENCIAS MÉDICAS Y DE LA SALUDmedicine.drug_classInmunologíaadoptive cell transfer; checkpoint blockers; dendritic cell-based interventions; DNA-based vaccines; immunostimulatory cytokines; peptide-based vaccines; oncolytic viruses; Toll-like receptor agonistsMonoclonal antibodydendritic cell-based interventionsToll-like receptor agonistsRC025403 medical and health sciencesImmune systemAntigen[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologyadoptive cell transfer030304 developmental biologyIMMUNOTHERAPIESbusiness.industryCancerImmunotherapymedicine.diseaseR1Oncolytic virusoncolytic virusesImmunologybusinessOncotarget
researchProduct

Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development

2012

Advanced therapy medicinal products (ATMPs), including cell therapy products, form a new class of medicines in the European Union. Since the ATMPs are at the forefront of scientific innovation in medicine, specific regulatory framework has been developed for these medicines and implemented from 2009. The Committee for Advanced Therapies (CAT) has been established at the European Medicines Agency (EMA) for centralized classification, certification and evaluation procedures, and other ATMP-related tasks. Guidance documents, initiatives, and interaction platforms are available to make the new framework more accessible for small- and medium-sized enterprises, academia, hospitals, and foundation…

lcsh:Immunologic diseases. Allergymesenchymal stem/progenitor cellMesenchymal stem cells (MSC)ImmunologyReview ArticleCertificationBest interestsAgency (sociology)Hospital Exemption authorisationImmunology and AllergyMedicinemedia_common.cataloged_instanceProduct (category theory)European unionHospital Exemptionmedia_commonbusiness.industrynational competent authorityCommittee for Advanced TherapiesCell therapy medicinal product (CTMP)AuthorizationGuidance documentsCommittee for Advanced Therapies (CAT)Engineering managementNew product developmentadvanced therapy medicinal productlcsh:RC581-607businesscell therapy medicinal productAdvanced therapy medicinal product (ATMP)Frontiers in Immunology
researchProduct

Extracellular Vesicles as Biological Shuttles for Targeted Therapies.

2019

The development of effective nanosystems for drug delivery represents a key challenge for the improvement of most current anticancer therapies. Recent progress in the understanding of structure and function of extracellular vesicles (EVs)—specialized membrane-bound nanocarriers for intercellular communication—suggests that they might also serve as optimal delivery systems of therapeutics. In addition to carrying proteins, lipids, DNA and different forms of RNAs, EVs can be engineered to deliver specific bioactive molecules to target cells. Exploitation of their molecular composition and physical properties, together with improvement in bio-techniques to modify their content are critical iss…

liposomesMolecular compositionBioactive moleculesReviewExtracellular vesiclesCatalysislcsh:ChemistryInorganic Chemistry03 medical and health sciencesExtracellular Vesicles0302 clinical medicineDrug Delivery SystemsPlant-derived extracellular vesicleAnimalsHumanstarget therapiesTarget therapyPhysical and Theoretical ChemistryRNA Small Interferinglcsh:QH301-705.5Molecular BiologySpectroscopy030304 developmental biology0303 health sciencesDrug CarriersChemistryOrganic ChemistryGeneral MedicinePlantsComputer Science ApplicationsStructure and functionCell biologyLiposomeplant-derived extracellular vesicleslcsh:Biology (General)lcsh:QD1-999Pharmaceutical Preparations030220 oncology & carcinogenesisDrug deliverydrug deliveryExtracellular vesicleNanocarriersDrug carrierInternational journal of molecular sciences
researchProduct

Severe asthma at COVID-19 time: what is new on biologic therapies.

2021

medicine.medical_specialty2019-20 coronavirus outbreakAsthma therapyCoronavirus disease 2019 (COVID-19)business.industrySevere asthmaBiologic therapiesMEDLINECOVID-19General MedicineSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.diseaseSeverity of Illness IndexAsthmaAsthma; COVID-19; Humans; Severity of Illness Index; Biological TherapyBiological TherapyInternal medicineSeverity of illnessmedicineHumansbusinessAsthmaHumanMinerva medica
researchProduct

Non-glycemic effects of pioglitazone and incretin-based therapies.

2013

Atherosclerosis and cardiovascular events are highly prevalent and represent the major cause of mortality in patients with type 2 diabetes. Therefore, there is significant interest in the non-glycemic properties of anti-diabetic agents, particularly on those that are effective on cardiovascular risk factors. Thiazolidinediones and incretin-based therapies (IBTs) represent some of the most recent treatment options approved for the management of type 2 diabetes; these agents have shown important glycemic effects, as well as a number of non-glycemic effects. The latter include those on body weight, inflammation, hypertension and dyslipidemia, thus impacting the different components of the meta…

medicine.medical_specialtyAtherosclerosis cardiovascular events type 2 diabetes pioglitazone incretin-based therapiesClinical BiochemistryMEDLINEIncretinType 2 diabetesPharmacologyIncretinsDrug DiscoverymedicineHumansHypoglycemic AgentsIn patientIntensive care medicineGlycemicDyslipidemiasPharmacologyPioglitazonebusiness.industryBody Weightmedicine.diseaseCardiovascular DiseasesMolecular MedicineThiazolidinedionesMetabolic syndromebusinessPioglitazoneDyslipidemiamedicine.drug
researchProduct

Update on the effects of graded motor imagery and mirror therapy on complex regional pain syndrome type 1: A systematic review.

2017

Graded motor imagery (GMI) and mirror therapy (MT) is thought to improve pain in patients with complex regional pain syndrome (CRPS) types 1 and 2. However, the evidence is limited and analysis are not independent between types of CRPS. The purpose of this review was to analyze the effects of GMI and MT on pain in independent groups of patients with CRPS types 1 and 2. Searches for literature published between 1990 and 2016 were conducted in databases. Randomized controlled trials that compared GMI or MT with other treatments for CRPS types 1 and 2 were included. Six articles met the inclusion criteria and were classified from moderate to high quality. The total sample was composed of 171 p…

medicine.medical_specialtyCausalgiaImagery PsychotherapyPopulationPhysical Therapy Sports Therapy and Rehabilitationlaw.invention03 medical and health sciences0302 clinical medicineMotor imageryPhysical medicine and rehabilitationRandomized controlled triallawmedicineHumansOrthopedics and Sports MedicineIn patient030212 general & internal medicineeducationPain Measurementeducation.field_of_studyMind-Body TherapiesRehabilitationChronic painmedicine.diseaseReflex Sympathetic DystrophyComplex regional pain syndromeMirror therapySample size determinationPhysical therapyPsychology030217 neurology & neurosurgeryComplex Regional Pain SyndromesJournal of back and musculoskeletal rehabilitation
researchProduct

Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).

2016

Abstract Purpose Management of giant cell arteritis (GCA, Horton's disease) involves many uncertainties. This work was undertaken to establish French recommendations for GCA management. Methods Recommendations were developed by a multidisciplinary panel of 33 physicians, members of the French Study Group for Large Vessel Vasculitis (Groupe d’etude francais des arterites des gros vaisseaux [GEFA]). The topics to be addressed, selected from proposals by group members, were assigned to subgroups to summarize the available literature and draft recommendations. Following an iterative consensus-seeking process that yielded consensus recommendations, the degree of agreement among panel members was…

medicine.medical_specialtyConsensusConsensus Development Conferences as TopicGiant Cell ArteritisDiseaseRecommendations03 medical and health sciences0302 clinical medicineLarge vessel vasculitisDiagnosismedicineInternal MedicineHumans030212 general & internal medicineIntensive care medicineExpert TestimonySocieties Medical030203 arthritis & rheumatologyModalitiesbusiness.industryBiologic therapiesGastroenterologyTemporal artery biopsymedicine.diseaseSurgeryTreatmentGiant cell arteritisRegimenAdjunctive treatmentCommittee MembershipFrancebusinessAlgorithmsLa Revue de medecine interne
researchProduct